ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,040.04
      1.10%
      US Tech 100
      21,199.60
      1.36%
      Dow Jones
      43,297.03
      0.91%
      Brent Oil
      73.285
      0.00%
      Bitcoin
      97,940.23
      -0.75%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Revolution Medicines Inc (RVMD) Quote

      Revolution Medicines Inc

      Revolution Medicines Inc (RVMD)

      NASDAQ
      44.39
      0.46
      (1.05%)
      Closed December 24 4:00PM
      Delayed by 15 minutes
      44.39
      0.00
      (0.00%)
      After Hours: 5:00PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      44.39
      Bid
      42.00
      Ask
      54.00
      Volume
      350,019
      43.49 Day's Range 44.42
      25.93 52 Week Range 62.40
      Market Cap
      7.467B
      Previous Close
      43.93
      Open
      44.00
      Last Trade
      74
      @
      44
      Last Trade Time
      Financial Volume
      $ 15,410,698
      VWAP
      44.0282
      Average Volume (3m)
      1,602,921
      Shares Outstanding
      168,219,391
      Dividend Yield
      -
      PE Ratio
      -0.07
      Earnings Per Share (EPS)
      -2.59
      Revenue
      11.58M
      Net Profit
      -436.37M

      About Revolution Medicines Inc

      Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include R... Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.revmed.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Revolution Medicines Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RVMD. The last closing price for Revolution Medicines was $43.93. Over the last year, Revolution Medicines shares have traded in a share price range of $ 25.93 to $ 62.40.

      Revolution Medicines currently has 168,219,391 shares outstanding. The market capitalization of Revolution Medicines is $7.39 billion. Revolution Medicines has a price to earnings ratio (PE ratio) of -0.07.

      Ask ADVFN Intelligence (AI)

      RVMD Latest News

      More News

      Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

      REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

      December 05 2024
      GlobeNewswire Inc.

      Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

      REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

      December 03 2024
      GlobeNewswire Inc.

      Revolution Medicines Announces Commencement of Public Offering of Common Stock

      REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

      December 02 2024
      GlobeNewswire Inc.

      Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

      Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial Phase 1/1b proof-of-concept...

      December 02 2024
      GlobeNewswire Inc.

      Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

      REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

      November 27 2024
      GlobeNewswire Inc.

      Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

      Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for...

      November 06 2024
      GlobeNewswire Inc.

      Revolution Medicines to Participate in Upcoming Investor Conferences

      REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...

      November 05 2024
      GlobeNewswire Inc.

      Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

      REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...

      October 30 2024
      GlobeNewswire Inc.

      Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

      First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC Investor webcast to be held Friday...

      October 25 2024
      GlobeNewswire Inc.

      Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

      Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday...

      October 23 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.71-1.5742793791645.146.0542.53154539843.85266982CS
      4-13.82-23.741625150358.2159.7242.53215662947.80301649CS
      12-0.93-2.0520741394545.3262.442.53160292150.85254443CS
      265.9615.508717148138.4362.436.5144436147.53465639CS
      5216.6860.194875496227.7162.425.93139559440.81297267CS
      15616.8961.418181818227.562.414.08123692630.2937676CS
      26015.0451.243611584329.3562.414.0894521130.97152486CS

      RVMD - Frequently Asked Questions (FAQ)

      What is the current Revolution Medicines share price?
      The current share price of Revolution Medicines is $ 44.39
      How many Revolution Medicines shares are in issue?
      Revolution Medicines has 168,219,391 shares in issue
      What is the market cap of Revolution Medicines?
      The market capitalisation of Revolution Medicines is USD 7.39B
      What is the 1 year trading range for Revolution Medicines share price?
      Revolution Medicines has traded in the range of $ 25.93 to $ 62.40 during the past year
      What is the PE ratio of Revolution Medicines?
      The price to earnings ratio of Revolution Medicines is -0.07
      What is the cash to sales ratio of Revolution Medicines?
      The cash to sales ratio of Revolution Medicines is 2.62
      What is the reporting currency for Revolution Medicines?
      Revolution Medicines reports financial results in USD
      What is the latest annual turnover for Revolution Medicines?
      The latest annual turnover of Revolution Medicines is USD 11.58M
      What is the latest annual profit for Revolution Medicines?
      The latest annual profit of Revolution Medicines is USD -436.37M
      What is the registered address of Revolution Medicines?
      The registered address for Revolution Medicines is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
      What is the Revolution Medicines website address?
      The website address for Revolution Medicines is www.revmed.com
      Which industry sector does Revolution Medicines operate in?
      Revolution Medicines operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      BAOSBaosheng Media Group Holdings Ltd
      $ 7.10
      (310.40%)
      		58.74M
      HOURHour Loop Inc
      $ 4.40
      (207.69%)
      		97.42M
      GTIGraphjet Technology
      $ 0.61
      (168.72%)
      		265.48M
      CREVCarbon Revolution Public Ltd
      $ 9.16
      (135.48%)
      		26.95M
      AVGRAvinger Inc
      $ 1.45
      (125.72%)
      		107.53M
      SLGLSol Gel Technologies Ltd
      $ 0.9798
      (-40.62%)
      		3.07M
      DRCTDirect Digital Holdings Inc
      $ 3.71
      (-32.55%)
      		23.82M
      CHEKCheck Cap Ltd
      $ 1.55
      (-31.11%)
      		3.49M
      SYTASiyata Mobile Inc
      $ 0.5178
      (-30.83%)
      		2.63M
      BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF
      $ 15.47
      (-30.38%)
      		147.98k
      SVMHSRIVARU Holding Ltd
      $ 0.0338
      (20.71%)
      		280.27M
      GTIGraphjet Technology
      $ 0.61
      (168.72%)
      		265.48M
      LITMSnow Lake Resources Ltd
      $ 0.5849
      (52.84%)
      		181.22M
      LCIDLucid Group Inc
      $ 3.20
      (3.23%)
      		108.75M
      RGTIRigetti Computing Inc
      $ 11.35
      (3.56%)
      		108.38M

      RVMD Discussion

      View Posts
      Monksdream Monksdream 2 months ago
      RVMD under $50
      👍️0
      axelvento axelvento 9 months ago
      Dr Olive added: 'I’ve been working on pancreatic cancer for almost 20 years, and I’ve never seen preclinical results like these.

      'I think there is a real chance this approach will help change the standard of care for pancreatic cancer patients, but only clinical trials can determine that
      👍️0
      axelvento axelvento 9 months ago
      Breakthrough in fight against world's deadliest cancer - new drug shrunk up to 70% of pancreatic tumors in lab study

      https://www.dailymail.co.uk/health/article-13284461/pancreatic-cancer-breakthrough-deadliest-disease-study.html
      👍️0
      Monksdream Monksdream 9 months ago
      RVMD over $30
      👍️0
      Monksdream Monksdream 10 months ago
      RVMD 10Q. 2/26
      👍️0

      Your Recent History

      NASDAQ
      RVMD
      Revolution Medicines
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads